Schilke Tobin, CFO of Crinetics Pharmaceuticals ($CRNX), made one open market sale of common shares in the last year, totaling about $266 thousand. The most recent sale occurred on March 3, 2026. This ranks 7,821st among 11,678 insiders in our database by sale value, compared to an average of $8.6 million per insider and 6.4 transactions. Tobin had no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 3, 2026 | Crinetics Pharmaceuticals, Inc. | $CRNX | Schilke Tobin | Chief Financial Officer | S | Common Stock | 6713 | $39.67 | 78,121.0000 | 94,548,000 | 7.91% | 0.01% |
| Feb. 23, 2026 | Crinetics Pharmaceuticals, Inc. | $CRNX | Schilke Tobin | Chief Financial Officer | A | Common Stock | 32000 | $0.00 | 84,834.0000 | 94,548,000 | 60.57% | 0.03% |
| Feb. 23, 2026 | Crinetics Pharmaceuticals, Inc. | $CRNX | Schilke Tobin | Chief Financial Officer | A | Stock Option (Right to Buy) | 50000 | $0.00 | 50,000.0000 | 94,548,000 | 9999.99% | 0.05% |
| March 10, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Schilke Tobin | Chief Financial Officer | A | Common Stock | 52000 | $0.00 | 52,000.0000 | 92,926,000 | 9999.99% | 0.06% |
| March 10, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Schilke Tobin | Chief Financial Officer | A | Stock Option (Right to Buy) | 80000 | $0.00 | 80,000.0000 | 92,926,000 | 9999.99% | 0.09% |